Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

Abstract

Introduction: Uterine leiomyoma is the most common benign tumor in women during the reproductive years. Menorrhagia is the common symptom and accounts for the most frequent indication for hysterectomy. Thus, development of a novel drug for non-surgical treatment of uterine leiomyoma is needed for the betterment of women's health.

Area covered: This review introduces a translational research initiated by use of the levonorgestrel-releasing intrauterine system (LNG-IUS) for contraceptive purposes. During follow-up, a patient informed that heavy menstrual bleeding caused by uterine myoma was strikingly reduced after the insertion of device. The patient's unexpected comment led the authors to perform clinical trials of LNG-IUS for the management of menorrhagia in women with uterine myomas and striking reduction in menorrhagia was obtained by the use of LNG-IUS. MRI examination, however, revealed that the volume of myomas decreased in some, but increased in the other instances. This unexpected finding with MRI directed the authors to characterize the effects of progesterone (P4) and progesterone receptor modulators (PRMs) on uterineleiomyoma cell growth in vitro.

Expert opinion: In consistence with the in vitro data obtained, randomized controlled clinical trials of PRMs in patients with uterine leiomyomas at several institutions have demonstrated that oral administration of PRMs (asoprisnil and ulipristal) for 3 months reduced leiomyoma volume, resulting in a significant improvement of the associated symptoms. However, a novel pattern of PRM-associated endometrial changes was recognized in the endometrial pathology, demonstrating unusual epithelial types not seen in the normal menstrual cycle of a premenstrual woman. Thus, follow-up studies to determine whether the novel endometrial changes remain, disappear or progress to something else are needed for the possible long-term use of PRMs for the treatment of uterine leiomyoma.

Keywords:

• angiogenic factor
• apoptosis
• asoprisnil
• clinical trial
• CP8947
• extracelullar matrix component
• growth factor
• levonorgestrel-releasing IUS
• menorrhagia
• PRM-associated endometrial change
• progesterone
• progesterone receptor modulator
• proliferation
• ulipristal
• uterine leiomyoma

Acknowledgments

The authors wish to thank Population Council (New York, USA) for supplying LNG-IUS for the clinical study in Japan, and TAP Pharmaceutical Products, Inc. (Lake Forest, IL, USA) and HRA Pharma (Paris, France) for kindly providing us with asoprisnil and ulipristal, respectively, for the in vitro studies.

Notes

This box summarizes key points contained in the article.